Lava Therapeutics Nv Expected To Post A Loss Of 33 Cents A Share: Earnings Preview

LAVA Therapeutics NV

29/11/2024 13:32

* LAVA Therapeutics NV  LVTX.OQ   LVTX.O  is expected
to show a
fall in quarterly revenue when it reports  results on December 2
(estimated) for the period ending September 30 2024
    * 
    * ​LSEG's mean analyst estimate for LAVA Therapeutics NV is
for a
loss of 33 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for LAVA
Therapeutics
NV is $6.00​, above​ its last closing price of $1.60. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.37       -0.36      -0.31     Beat    13.9
 Mar. 31 2024  -0.11       -0.12      -0.02     Beat    84
 Dec. 31 2023  0.33        -0.12      -0.24     Missed  -92​
 Sep. 30 2023  -0.49       -0.49      -0.34     Beat    30.6
 ​​Jun.        -0.47       -0.47      -0.48     Missed  -1.4
 30 2023                                                
 Mar. 31 2023  -0.52       -0.52      -0.53     Missed  -1.9​
 Dec. 31 2022              -0.63      -0.57     Beat    10.1
 Sep. 30 2022  0.00        -0.14      0.04      Beat    128.7
 This summary was machine generated November 29 at 13:32 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)